Detailed narrative
FG3246 Program Update in MCRPC
Kyntra Bio is developing FG3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, and its companion PET imaging agent FG3180, for metastatic castration-resistant prostate cancer (MCRPC). CD46 is highlighted as a novel, tumor-selective target with high expression in prostate cancer and lower interpatient variability compared to PSMA.
The ADC combines the YS5 antibody with an MMAE payload, differentiating it from PSMA-targeted therapies and representing a significant commercial opportunity as a companion diagnostic.
FG3246 Clinical Data Highlights
In a Phase 1 monotherapy trial, FG3246 demonstrated a median radiographic progression-free survival (RPFS) of 8.7 months and a PSA50 response of 36% in heavily pretreated, biomarker-unselected MCRPC patients. A Phase 1B2 investigator-initiated study combining FG3246 with enzalutamide showed encouraging anti-tumor activity with a median RPFS of 7 months, and 10.1 months in patients who had progressed on only one prior ARPI, with a PSA50 response of 40% in that subgroup.
FG3246 Phase 2 Trial Design and Interim Analysis
The ongoing Phase 2 monotherapy trial is enrolling 75 patients in the post-1ARPI pre-chemo setting across three dose levels (1.8, 2.4, and 2.7 mg/kg). Key design elements include primary prophylaxis with GCSF to mitigate neutropenia and enrolling patients earlier in the disease progression, aiming to improve upon Phase 1 results.
The interim analysis of 36 patients is on track for Q4 2026, with mature RPFS data expected throughout 2027.
Roxadustat Program in Lower-Risk MDS
Roxadustat is being developed for anemia due to lower-risk myelodysplastic syndromes (MDS), addressing a significant unmet need for an effective, durable, and convenient oral treatment. A post-hoc analysis of the Phase III Matterhorn study showed 36% of high transfusion burden patients achieved transfusion independence for at least eight weeks, compared to 7% in the placebo group, with results highly similar to recently approved therapies.
Roxadustat Phase 3 and RS-Negative Opportunity
The Phase III trial protocol has been finalized, with a primary endpoint of eight-week transfusion independence over the first 24 weeks. Roxadustat demonstrated similar rates of transfusion independence across both RS-positive and RS-negative patients in the Matterhorn study. This positions it favorably, especially in the RS-negative segment, which represents over 50% of lower-risk MDS patients and where current market leaders have limited efficacy.
Financial Performance and Outlook
For Q2 FY26, Kyntra Bio reported negative total revenue of $1.5 million and increased total operating costs to $16.1 million. Despite this, the company achieved a net income from continuing operations of $12 million ($2.96 per share), a significant improvement from a net loss of $13.7 million ($3.38 per share) in the prior year.
The company expects a cash runway into 2028, supporting its pipeline investments.
Strategic Vision and Upcoming Catalysts
Kyntra Bio is focused on disciplined execution for both FG3246 and Roxadustat programs. Key upcoming catalysts include the interim analysis of the FG3246 Phase 2 trial and the initiation of the Roxadustat Phase III trial, both expected in Q4 2026. The company is evaluating both internal development and strategic partnerships for Roxadustat, considering economic and operational factors.